Updates on Vaccine Safety and Post-Licensure Surveillance for Adverse Events Following Immunization in South Korea, 2005-2017

被引:7
|
作者
Yoon, Dongwon [1 ]
Kim, Ju Hwan [1 ]
Lee, Hyesung [1 ]
Shin, Ju-Young [1 ]
机构
[1] Sungkyunkwan Univ, Sch Pharm, 2066 Seobu Ro, Suwon 16419, South Korea
关键词
Vaccines; product surveillance; postmarketing; drug-related side effects and adverse reactions; adverse drug reaction reporting systems; signal detection; PREGNANCY; MANAGEMENT; SYSTEM;
D O I
10.3349/ymj.2020.61.7.623
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose: Vaccine hesitancy is among the top ten threats to global health, and access to precise data on adverse events following immunization (AEFIs) is imperative to alleviate public concerns surrounding vaccines. This study aimed to present the overall trends of AEFIs reported in South Korea. Materials and Methods: We evaluated the trends of AEFIs using the Korea Institute of Drug Safety & Risk Management-Korea Adverse Event Reporting System database between January 2005 and December 2017. AEFIs were classified into five categories to evaluate associations between vaccines and AEFIs through a case-non-case study: neurologic reactions, general systemic reactions, local reactions, allergic reactions, and others. Results: Among 54378 reported adverse events (AEs) associated with all vaccines approved in South Korea, more than half (56.7%) occurred following influenza vaccination, followed by the pneumococcal (11.6%) and Bacillus Calmette-Guerin (BCG) vaccines (5.0%). After immunization with most vaccines, general systemic reactions were most common, followed by local and neurologic reactions. Adjusted reporting odds ratios were calculated for all neurologic, general, local, and allergic reactions: of all vaccines, rotavirus [neurologic 2.43, 95% confidence interval (CI), 2.25-2.62], BCG (general; 2.20, 95% CI, 1.91-2.53), BCG (local; 3.15, 95% CI, 2.69-3.68), and Japanese encephalitis (allergic 2.38, 95% CI, 1.98-2.87) vaccines showed the highest values. Conclusion: The majority of reported AEFIs were non-serious and mostly general systemic reactions. Sufficient knowledge on the AEFIs would secure public confidence on the safety of vaccines, thereby reducing public health burden from vaccine-preventable diseases.
引用
收藏
页码:623 / 630
页数:8
相关论文
共 50 条
  • [2] A Bayesian approach to sequential analysis in post-licensure vaccine safety surveillance
    Li, Rongxia
    Stewart, Brock
    Rose, Charles
    [J]. PHARMACEUTICAL STATISTICS, 2020, 19 (03) : 291 - 302
  • [3] Vaccine Safety and Surveillance for Adverse Events Following Immunization (AEFI) in India
    Joshi, Jyoti
    Das, Manoja Kumar
    Polpakara, Deepak
    Aneja, Satinder
    Agarwal, Mahesh
    Arora, Narendra Kumar
    [J]. INDIAN JOURNAL OF PEDIATRICS, 2018, 85 (02): : 139 - 148
  • [4] Vaccine Safety and Surveillance for Adverse Events Following Immunization (AEFI) in India
    Jyoti Joshi
    Manoja Kumar Das
    Deepak Polpakara
    Satinder Aneja
    Mahesh Agarwal
    Narendra Kumar Arora
    [J]. The Indian Journal of Pediatrics, 2018, 85 : 139 - 148
  • [5] Surveillance for Adverse Events Following Receipt of Pandemic 2009 H1N1 Vaccine in the Post-Licensure Rapid Immunization Safety Monitoring (PRISM) System, 2009-2010
    Yih, W. Katherine
    Lee, Grace M.
    Lieu, Tracy A.
    Ball, Robert
    Kulldorff, Martin
    Rett, Melisa
    Wahl, Peter M.
    McMahill-Walraven, Cheryl N.
    Platt, Richard
    Salmon, Daniel A.
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2012, 175 (11) : 1120 - 1128
  • [6] Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine using the national adverse event following immunization surveillance system from Zhejiang province, 2018-2020
    Hu, Yu
    Pan, Xuejiao
    Shen, Linzhi
    Chen, Fuxing
    Wang, Ying
    Liang, Hui
    Chen, Yaping
    Lv, Huakun
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2021, 17 (12) : 5447 - 5453
  • [7] Post-licensure safety surveillance of 23-valent pneumococcal polysaccharide vaccine in the Vaccine Adverse Event Reporting System (VAERS), 1990-2013
    Miller, Elaine R.
    Moro, Pedro L.
    Cano, Maria
    Lewis, Paige
    Bryant-Genevier, Marthe
    Shimabukuro, Tom T.
    [J]. VACCINE, 2016, 34 (25) : 2841 - 2846
  • [8] Post-licensure safety surveillance of zoster vaccine live (Zostavax®) in the United States, Vaccine Adverse Event Reporting System (VAERS), 2006-2015
    Miller, Elaine R.
    Lewis, Paige
    Shimabukuro, Tom T.
    Su, John
    Moro, Pedro
    Woo, Emily Jane
    Jankosky, Christopher
    Cano, Maria
    [J]. HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2018, 14 (08) : 1963 - 1969
  • [9] Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine
    Hansen, J.
    Zhang, L.
    Klein, N. P.
    Robertson, C. A.
    Decker, M. D.
    Greenberg, D. P.
    Bassily, E.
    Baxter, R.
    [J]. VACCINE, 2017, 35 (49) : 6879 - 6884
  • [10] Surveillance of adverse events following varicella vaccine immunization in Jiangsu province, China from 2017 to 2023
    Zhang, Lei
    Fu, YaLi
    Wang, Wen
    Liu, YuanBao
    Hu, Ran
    Wang, Zhiguo
    Sun, Xiang
    [J]. BMC INFECTIOUS DISEASES, 2024, 24 (01)